Third-party validation, including HPLC/MS testing where applicable, supports consistency, traceability, and reproducibility across controlled research applications
Common Side Effects Gastrointestinal (additive): Nausea, vomiting, diarrhea, constipation and reduced appetite are the most common events and are amplified by stacking two agents that act on gut motility the dominant adverse-event category in REDEFINE [1] [2]
More serious but rare adverse events include pancreatitis (0.2% incidence), gallbladder disease requiring surgical intervention, and medullary thyroid carcinoma risk in genetically predisposed individuals (contraindicated in patients with personal or family history of MTC or MEN2 syndrome)
AOD9604 is studied for stimulating fat breakdown specifically, without the bone growth, muscle growth, or insulin resistance effects typically associated with full-length growth hormone administration
This graduated approach allows your body to adjust to increased growth hormone signaling without overwhelming the pituitary axis.
